Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,134.17% | -512.44% | -540.11% | -607.67% | 97.28% |
| Total Depreciation and Amortization | -- | -190.05% | -193.19% | -196.40% | -- |
| Total Amortization of Deferred Charges | -59.12% | -0.75% | -23.24% | -35.32% | -44.60% |
| Total Other Non-Cash Items | 16.70% | -44.39% | 133.86% | 63.30% | 91.25% |
| Change in Net Operating Assets | -187.55% | -139.28% | -167.92% | -161.75% | 349.97% |
| Cash from Operations | -146.23% | -133.84% | -150.71% | -159.62% | 257.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.82% | -- | -- | -- | -- |
| Issuance of Common Stock | 2,408.41% | 72.40% | -39.67% | -28.87% | 3.21% |
| Repurchase of Common Stock | 42.41% | 45.72% | -495.00% | -729.87% | -728.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.95% | 100.00% | 100.00% | 100.00% | -- |
| Cash from Financing | 266.19% | -340.07% | -350.49% | -328.19% | -305.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.03% | -165.80% | -186.66% | -186.93% | 227.23% |